- 主题发起人 confiture
- 发布时间 2020-04-12
可能是这句话
The viruses bind to the antigen binding site at the other end of the antibody. ADE is common in cells cultured in the laboratory, but rarely occurs in vivo except for dengue virus
ADE简单说：就是说身体不好的人会多次感染新冠肺炎直到死掉？
医学完全不懂，但看今天国内新闻说武汉3月23日—4月10日，新增无症状感染者共447人。其中，只有1例本地感染者转为确诊病例，搜索发现密切接触者1291人，目前未发现续发无症状感染者或病例。这个数据还是相信的，否则国内大量已测或未测的无症状感染者或康复有抗体的不是分分钟能引起第二波复发？或者说，疫苗没有成功搞出来前，人类完全无法控制新冠？
目前没听说谁复发的，只是没有真的好假阴放回去的可能恶化，方舟子是这样解释的。我持乐观态度。除非人类真的太罪恶，上帝要让他灭亡
贴读到一个文章如下。
ADE has posed a similar challenge in the creation of vaccines for infections including dengue and a cat coronavirus, feline infectious peritonitis virus (FIPV). In one study, cats vaccinated against FIPV got sicker than cats left unvaccinated (5). Again, the virus-specific antibody increased the virus uptake by macrophages.
Yet some experts doubt that ADE is relevant for COVID-19. “We have no evidence that ADE is actually occurring in human patients,” says Angela Rasmussen, a virologist at Columbia University Mailman School of Public Health in New York, citing such findings.
In principle, anecdotal reports of COVID-19 reinfections in China (6) could lend credence to relevance of ADE—that is, the production of antibodies to the virus (resulting from immunization or an initial natural infection) ends up enhancing entry of the virus into cells. But Rasmussen and other experts underscore the lack of real evidence for COVID-19 reinfections. Any repeat cases so far reported, they say, could be explained by false negative tests between the positive tests. “It’s not clear that patients were ever not infected,” says Rasmussen.
And there is some preliminary experimental evidence casting doubt on ADE. Two papers published in March in Cell show that antibodies against the original SARS infection, which emerged in China in 2002, could also block entry of SARS-CoV-2 into human cells. Another preprint study showed that rhesus macaques infected with SARS-CoV-2 and allowed to recover were not infected after a second exposure to the virus. Unless future data correlate severe COVID-19 cases with original SARS infections—or other diagnostic, pathology, or clinical findings indicate ADE—then there is “not much to go on that suggests ADE is a factor,” Rasmussen says.
贴读到一个文章如下。
ADE has posed a similar challenge in the creation of vaccines for infections including dengue and a cat coronavirus, feline infectious peritonitis virus (FIPV). In one study, cats vaccinated against FIPV got sicker than cats left unvaccinated (5). Again, the virus-specific antibody increased the virus uptake by macrophages.
Yet some experts doubt that ADE is relevant for COVID-19. “We have no evidence that ADE is actually occurring in human patients,” says Angela Rasmussen, a virologist at Columbia University Mailman School of Public Health in New York, citing such findings.
In principle, anecdotal reports of COVID-19 reinfections in China (6) could lend credence to relevance of ADE—that is, the production of antibodies to the virus (resulting from immunization or an initial natural infection) ends up enhancing entry of the virus into cells. But Rasmussen and other experts underscore the lack of real evidence for COVID-19 reinfections. Any repeat cases so far reported, they say, could be explained by false negative tests between the positive tests. “It’s not clear that patients were ever not infected,” says Rasmussen.
And there is some preliminary experimental evidence casting doubt on ADE. Two papers published in March in Cell show that antibodies against the original SARS infection, which emerged in China in 2002, could also block entry of SARS-CoV-2 into human cells. Another preprint study showed that rhesus macaques infected with SARS-CoV-2 and allowed to recover were not infected after a second exposure to the virus. Unless future data correlate severe COVID-19 cases with original SARS infections—or other diagnostic, pathology, or clinical findings indicate ADE—then there is “not much to go on that suggests ADE is a factor,” Rasmussen says.
最后编辑: 2020-04-14
看看其他国家的研究结果
Similar threads
2022-12-31有新赞
全楼:1.23
popyard
中国话题
2024回国记录
- 0.07 超赞 赏
- Jacklyns ,#485
- 2024-01-18
- 聊天・灌水・娱乐・新闻・时事
2024-01-28有新回复
全楼:0.96
wisdom
